20/20 Biolabs, Inc. (AIDX) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Oct 5Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29Nov 3

Key dataNov 3, 2026

Open$0.24

From 52W high−99.02%

Volume425788.00

Market cap$3.14M

P/E (TTM)—

P/S (TTM)1.5x

Div yield—

Key dataNov 3, 2026

Open

$0.24

From 52W high

−99.02%

Volume

425788.00

Market cap

$3.14M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.1x

P/E (TTM)

—

RSI (14)

33.2

MomentumView details →

1D Return

−0.04%

YTD Return

—

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.1x

EV/Sales

0.3x

P/S (TTM)

1.5x

P/B (TTM)

1.0x

ProfitabilityView details →

Gross Margin

31.52%

Net Margin

−285.00%

EBITDA Margin

−235.10%

ROE (TTM)

−184.04%

ROA (TTM)

−94.96%

Asset Turnover

0.34x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

−43.03%

EPS CAGR 3Y

+48.28%

EBITDA YoY

—

MomentumView details →

1D Return

−0.04%

YTD Return

—

1Y Return

—

RSI (14)

33.2

vs 50D SMA

−41.52%

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

0.18x

Current Ratio

1.99x

Quick Ratio

1.95x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.26

EPS Surprise

−116.67%

Beats (12Q)

0/12

Next Q EPS Est

−$0.07

Avg Surprise (4Q)

−116.67%

Rev Surprise

14.87%

Financials snapshotView financials →

Revenue (TTM)

2.04M

Net Income (TTM)

−5.81M

Op. CF (TTM)

−2.79M

Latest newsMore news →

20/20 Biolabs, Inc. announced that it will host an investor webinar on November 4, 2026, at 12:00 p.m. Eastern Time, covering OneTest commercial expansion, growth strategy, 2027 licensing plans, potential acquisitions, FDA strategy, and firefighter cancer screening initiatives.6d ago

Nasdaq notified 20/20 Biolabs, Inc. on September 3, 2026 that it failed to comply with the $2.5 million stockholders' equity requirement under Listing Rule 5550(b)(1), giving the company 45 calendar days to submit a compliance plan.55d ago

Similar companies

Autonomix Medical, Inc. Common StockAMIX IceCure Medical LtdICCM Vivos Therapeutics, Inc.VVOS Baird Medical Investment Holdings LimitedBDMD Inspira Technologies Oxy B.H.N. Ltd.IINNW Beyond Air, Inc.XAIR Find similar companies →

Latest newsMore news →

20/20 Biolabs, Inc. announced that it will host an investor webinar on November 4, 2026, at 12:00 p.m. Eastern Time, covering OneTest commercial expansion, growth strategy, 2027 licensing plans, potential acquisitions, FDA strategy, and firefighter cancer screening initiatives.6d ago Nasdaq notified 20/20 Biolabs, Inc. on September 3, 2026 that it failed to comply with the $2.5 million stockholders' equity requirement under Listing Rule 5550(b)(1), giving the company 45 calendar days to submit a compliance plan.55d ago